337 related articles for article (PubMed ID: 28332172)
1. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
2. Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
Catalano A; Morabito N; Agostino RM; Basile G; Gaudio A; Atteritano M; Natale G; Xourafa A; Morini E; Adamo V; Lasco A
Menopause; 2017 Jan; 24(1):85-91. PubMed ID: 27575547
[TBL] [Abstract][Full Text] [Related]
3. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
4. Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.
Camozzi V; Lumachi F; Mantero F; Piccolo M; Luisetto G
Osteoporos Int; 2003 Jul; 14(7):602-8. PubMed ID: 12730752
[TBL] [Abstract][Full Text] [Related]
5. Performance of five phalangeal QUS parameters in the evaluation of gonadal-status, age and vertebral fracture risk compared with DXA.
Albanese CV; Cepollaro C; de Terlizzi F; Brandi ML; Passariello R
Ultrasound Med Biol; 2009 Apr; 35(4):537-44. PubMed ID: 19097682
[TBL] [Abstract][Full Text] [Related]
6. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
8. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a new quantitative ultrasound calcaneus measurement: precision and discrimination of hip fractures in elderly women compared with dual X-ray absorptiometry.
He YQ; Fan B; Hans D; Li J; Wu CY; Njeh CF; Zhao S; Lu Y; Tsuda-Futami E; Fuerst T; Genant HK
Osteoporos Int; 2000; 11(4):354-60. PubMed ID: 10928226
[TBL] [Abstract][Full Text] [Related]
10. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
11. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
12. Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men.
Gonnelli S; Cepollaro C; Gennari L; Montagnani A; Caffarelli C; Merlotti D; Rossi S; Cadirni A; Nuti R
Osteoporos Int; 2005 Aug; 16(8):963-8. PubMed ID: 15599495
[TBL] [Abstract][Full Text] [Related]
13. Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome.
Cortet B; Cortet C; Blanckaert F; d'Herbomez M; Marchandise X; Wémeau J-L ; Decoulx M; Dewailly D
Osteoporos Int; 2001; 12(2):117-23. PubMed ID: 11303711
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
15. [Bone mineral density in postmenopausal women with proximal femoral fractures--comparative study between quantitative ultrasonometry and gold standard DXA].
Schnabel M; Eser G; Ziller V; Mann D; Mann E; Hadji P
Zentralbl Chir; 2005 Oct; 130(5):469-75. PubMed ID: 16220445
[TBL] [Abstract][Full Text] [Related]
16. The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
Ouchi Y; Nakatsukasa K; Sakaguchi K; Morita M; Koyama H; Matsuda T; Kato M; Konishi E; Ono H; Taguchi T
J Bone Miner Metab; 2021 Mar; 39(2):224-229. PubMed ID: 32889575
[TBL] [Abstract][Full Text] [Related]
17. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the longitudinal changes in quantitative ultrasound with dual-energy X-ray absorptiometry: the four-year effects of hormone replacement therapy.
Sahota O; San P; Cawte SA; Pearson D; Hosking DJ
Osteoporos Int; 2000; 11(1):52-8. PubMed ID: 10663359
[TBL] [Abstract][Full Text] [Related]
20. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
